Peter Cartwright may refer to: (wikipedia)
The more fundamental strategic review -- in particular as to whether any businesses get sold or not -- probably will happen, but not in the very short term.
Wednesday's the teaser, Thursday's the Full Monty. We should get a look at their R&D (research and development) strategy, pipeline, commercial strategy and an update on cost-cutting.
They are dragging a ball and chain behind them now.
There is an inexorable drift toward consolidation in the drug industry.
The pressure on SmithKline is clearly greater and, indeed, their actions have to show that. I expect the market will still work on the assumption that SmithKline will do a deal in the not-too-distant future.
The top-line growth rate was generally slower than expected, but that doesn't appear to have held profits back.
